Syntex' Toradol (ketorolac tromethamine), described by the company as being as effective a painkiller as a narcotic but without the addictive properties of a narcotic, has been linked to several deaths and a number of serious adverse reactions in Canada, reports the Montreal Gazette, a Canadian newspaper.
The drug has been associated with 18 cases of gastrointestinal bleeding, four of which have ended in death, and eight cases of severe allergic reactions, says the Canadian federal Health Department. There have been no reported associated deaths since July this year, noted Curt Appel, chief of adverse drug reaction monitoring. However, Mr Appel said that his department will begin investigating whether any other adverse reaction reports have been filed on Toradol.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze